Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors
- PMID: 15564725
- DOI: 10.1159/000082107
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors
Abstract
B lymphocyte stimulator (BLyS), also referred to as B cell activating factor of the TNF family, is a recently identified tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B cell development and homeostasis and it shares significant homology with another TNF superfamily member, a proliferation inducing ligand (APRIL). Currently, three receptors have been identified that transmit signals upon BLyS and APRIL binding and these include B cell maturation antigen, B cell activating factor receptor, and transmembrane activator and CAML interactor. The striking effects of BLyS on normal B cell maintenance and survival and the largely B lineage-restricted pattern of receptor expression, raises the possibility that these TNF family ligands and receptors may be involved not only in B cell autoimmunity, but also in the pathogenesis and maintenance of mature B lineage hematological malignancies. In this article, we will review the spectrum of human B lineage malignancies and discuss current evidence supporting a role for BLyS and APRIL in fueling the growth and survival of specific B cell malignancies.
Similar articles
-
The uncertain glory of APRIL.Cell Death Differ. 2003 Oct;10(10):1121-5. doi: 10.1038/sj.cdd.4401291. Cell Death Differ. 2003. PMID: 14502235 Review.
-
Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.Clin Lymphoma Myeloma. 2006 Sep;7(2):106-8. doi: 10.3816/CLM.2006.n.046. Clin Lymphoma Myeloma. 2006. PMID: 17026820 Review.
-
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k. Biochemistry. 2005. PMID: 15697217
-
The BAFF/APRIL system: an important player in systemic rheumatic diseases.Curr Dir Autoimmun. 2005;8:243-65. doi: 10.1159/000082106. Curr Dir Autoimmun. 2005. PMID: 15564724 Review.
-
BLyS and B cell homeostasis.Semin Immunol. 2006 Oct;18(5):318-26. doi: 10.1016/j.smim.2006.06.001. Epub 2006 Aug 22. Semin Immunol. 2006. PMID: 16931037 Review.
Cited by
-
New monoclonal antibodies on the horizon in multiple myeloma.Ther Adv Hematol. 2017 Feb;8(2):41-53. doi: 10.1177/2040620716682490. Epub 2016 Dec 26. Ther Adv Hematol. 2017. PMID: 28203341 Free PMC article. Review.
-
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050. Blood. 2019. PMID: 31558469 Free PMC article.
-
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.Blood. 2006 Apr 1;107(7):2882-8. doi: 10.1182/blood-2005-09-3552. Epub 2005 Nov 22. Blood. 2006. PMID: 16304043 Free PMC article.
-
Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.Leukemia. 2011 Feb;25(2):331-40. doi: 10.1038/leu.2010.261. Epub 2010 Nov 19. Leukemia. 2011. PMID: 21102426 Free PMC article.
-
The up-regulation expression of APRIL is a marker of glottic malignant disease.Eur Arch Otorhinolaryngol. 2014 Oct;271(10):2781-7. doi: 10.1007/s00405-013-2826-0. Epub 2013 Nov 26. Eur Arch Otorhinolaryngol. 2014. PMID: 24276470
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous